A dual character of flavonoids in influenza A virus replication and spread through modulating cell-autonomous immunity by MAPK signaling pathways

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Dong, Wenjuan ^a   Wei, Xiuli ^a   Zhang, Fayun ^a   Hao, Junfeng ^a   Huang, Feng ^a   Zhang, Chunling ^a   Liang, Wei ^a  

^a INSTITUTE OF BIOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVONOID; HESPERIDIN; KAEMPFEROL; KAEMPFEROL DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL; DNA REPLICATION; DOG; DRUG EFFECTS; HUMAN; IMMUNITY; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MDCK CELL LINE; METABOLISM; ORTHOMYXOVIRIDAE INFECTIONS; SIGNAL TRANSDUCTION; VIROLOGY; VIRUS REPLICATION;

ANIMALS; DNA REPLICATION; DOGS; FLAVONOIDS; HESPERIDIN; HUMANS; IMMUNITY; INFLUENZA A VIRUS; INFLUENZA, HUMAN; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KAEMPFEROLS; MADIN DARBY CANINE KIDNEY CELLS; MITOGEN-ACTIVATED PROTEIN KINASES; ORTHOMYXOVIRIDAE INFECTIONS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

EID: 84922623994     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07237     Document Type: Article

References (60)

1. Webster, R. G., Bean, W. J., Gorman, O. T., Chambers, T. M. & Kawaoka, Y. Evolution and ecology of influenza A viruses. Microbiol Rev. 56, 152-179 (1992
2. Cox, N. J. & Subbarao, K. Influenza. Lancet 354, 1277-1282 (1999
3. Moscona, A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353, 1363-1373 (2005
4. Gubareva, L. V., Kaiser, L. & Hayden, F. G. Influenza virus neuraminidase inhibitors. Lancet 355, 827-835 (2000
5. Gubareva, L. V. & Hayden, F. G. The anti-influenza activity of M2 and neuraminidase inhibotors [Kawaoka, Y. (Ed.)] [169-172] (Caister Academic, England, 2006
6. Fleming, D. M. Managing influenza: amantadine, rimantadine and beyond. Int. J. Clin. Pract. 55, 189-195 (2001
7. Hayden, F. Developing new antiviral agents for influenza treatment: what does the future hold?. Clin. Infect. Dis. 48, S3-S13 (2009
8. Moscona, A. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 360, 953-956 (2009
9. Lamb, R. A. & Krug, R. M. [Orthomyxoviridae: the viruses and their replication] Fields virology [Fields, B. N., Knipe, D. M. & Howley, P. M. (eds.)] [1487-1531] (Lippincott-Raven, Philadelphia, 2001
10. Muller, K. H, et al. Emerging cellular targets for influenza antiviral agents. Trends Pharmacol. Sci. 33, 89-99 (2012
11. Konig, R. et al.Human host factors required for influenza virus replication. Nature 463, 813-817 (2010
12. Ludwig, S. Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections. Biol. Che. 392, 837-847 (2011
13. Lee, S. M. Y. & Yen, H. L. Targeting the host or the virus: Current and novel concepts for antiviral approaches against influenza virus infection. Antiviral Res. 96, 391-404 (2012
14. Randow, F., MacMicking, J. D. & James, L. C. Cellular self-defense: How cellautonomous immunity protects against pathogens. Science 340, 701-706 (2013
15. Ronald, P. C. & Beutler, B. Plant and animal sensors of conserved microbial signatures. Science 330, 1061-1064 (2010
16. Levine, B., Mizushima, N. & Virgin, H. W. Autophagy in immunity and inflammation. Nature 469, 323-335 (2011
17. Neil, S. J. D., Zang, T. & Bieniasz, P. D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451, 425-430 (2008
18. Yan, N. & Chen, Z. J. J. Intrinsic antiviral immunity. Nat. Immunol. 13, 214-222 (2012
19. MacMicking, J. D. Interferon-inducible effector mechanisms in cell-Autonomous immunity. Nat. Rev. Immunol. 12, 367-382 (2012
20. Holm, C. K, et al. Virus-cell fusion as a trigger of innate immunity dependent on the adaptor STING. Nat. Immunol. 13, 737-743 (2012
21. Sadler, A. J. &Williams, B. R. G. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8, 559-568 (2008
22. Hazzalin, C. A. & Mahadevan, L. C. MAPK-regulated transcription: A continuously variable gene switch?. Nat. Rev. Mol. Cell Biol. 3, 30-40 (2002
23. Dong, C., Davis, R. J. & Flavell, R. A. MAP kinases in the immune response. Annu. Rev. Immunol. 20, 55-72 (2002
24. Wada, T. & Penninger, J. M. Mitogen-Activated protein kinases in apoptosis regulation. Oncogene 23, 2838-2849 (2004
25. Ludwig, S. Influenza viruses and MAP kinase cascades- Novel targets for an antiviral intervention?. Signal Transduction 7, 81-88 (2007
26. Mikkelsen, S. S, et al. RIG-I-mediated activation of p38 MAPK is essential for viral induction of interferon and activation of dendritic cells dependence on TRAF2 and TAK1. J. Biol. Chem. 284, 10774-10782 (2009
27. Hui, K. P. Y, et al. Induction of proinflammatory cytokines in primary human macrophages by influenza A virus (H5N1) is selectively regulated by IFN regulatory factor 3 and p38 MAPK. J. Immunol. 182, 1088-1098 (2009
28. Waetzig, V, et al. c-Jun N-Terminal kinases (JNKs) mediate pro-inflammatory actions of microglia. Glia 50, 235-246 (2005
29. Pleschka, S, et al. Influenza virus propagation is impaired by inhibition of the Raf/ MEK/ERK signalling cascade. Nat. Cell Biol. 3, 301-305 (2001
30. Kujime, K., Hashimoto, S., Gin, Y., Shimizu, K. &Horie, T. p38 mitogen-Activated protein kinase and c-Jun-NH2-Terminal kinase regulate RANTES production by influenza virus-infected human bronchial epithelial cells. J. Immunol. 164, 3222-3228 (2000
31. Ludwig, S, et al. Influenza virus-induced AP-1-dependent gene expression requires activation of the JNK signaling pathway. J. Biol. Chem. 276, 21990-21998(2001
32. Randall, R. E. & Goodbourn, S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 89, 1-47 (2008
33. Levy, D. E. & Garcia-Sastre, A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev. 12, 143-156 (2001
34. Doyle, S. E, et al. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity 17, 251-263 (2002
35. James, L. C., Keeble, A. H., Khan, Z., Rhodes, D. A. &Trowsdale, J. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc. Natl. Acad. Sci. 104, 6200-6205 (2007
36. McEwan, W. A, et al. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat. Immunol. 14, 327-336 (2013
37. Matsuzawa, T, et al. IFN-gamma Elicits Macrophage Autophagy via the p38 MAPK Signaling Pathway. J. Immunol. 189, 813-818 (2012
38. Bolz, D. D., Tenor, J. L. & Aballay, A. A conserved PMK-1/p38 MAPK is required in caenorhabditis elegans tissue-specific immune response to yersinia pestis infection. J. Biol. Chem. 285, 10832-10840 (2010
39. Kawli, T., He, F. L. & Tan, M. W. It takes nerves to fight infections: insights on neuro-immune interactions from C. elegans. Dis. Model Mech. 3, 721-731 (2010
40. Takauji, R, et al. CpG-DNA-induced IFN-Alpha production involves p38 MAPKdependent STAT1 phosphorylation in human plasmacytoid dendritic cell precursors. J. Leukoc. Biol. 72, 1011-1019 (2002
41. Tripathi, A. & Sodhi, A. Prolactin-induced production of cytokines in macrophages in vitro involves JAK/STAT and JNK/MAPK pathways. Int. Immunol. 20, 327-336 (2008
42. Fejer, G, et al. Key role of splenic myeloid DCs in the IFN-Alpha/beta response to adenoviruses in vivo. PLoS Pathog. 4, e1000208 (2008
43. Tamrakar, A. K, et al. NOD2 activation induces muscle cell-Autonomous innate immune responses and insulin resistance. Endocrinology 151, 5624-5637 (2010
44. Grandvaux, N., tenOever, B. R., Servant, M. J.&Hiscott, J. The interferon antiviral response: from viral invasion to evasion. Curr. Opin. Infec. Dis. 15, 259-267 (2002).
45. Costa-Pereira, A. P, et al. The antiviral response to gamma interferon. J. Virol. 76, 9060-9068 (2002
46. Malcolm, K. C. & Worthen, G. S. Lipopolysaccharide stimulates p38-dependent induction of antiviral genes in neutrophils independently of paracrine factors. J. Biol. Chem. 278, 15693-15701 (2003
47. Goh, K. C., Haque, S. J. & Williams, B. R. G. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J. 18, 5601-5608 (1999
48. Ramsauer, K, et al. p38 MAPK enhances STAT1-dependent transcription independently of Ser-727 phosphorylation. Proc.Natl. Acad. Sci. 99, 12859-12864 (2002
49. Saccani, S., Pantano, S. & Natoli, G. p38-dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat. Immunol. 3, 69-75 (2002
50. Humar, M, et al. The mitogen-Activated protein kinase p38 regulates activator protein 1 by direct phosphorylation of c-Jun. Int. J. Biochem. Cell Biol. 39, 2278-2288 (2007
51. Vignola, M. J., Kashatus, D. F., Taylor, G. A., Counter, C. M. & Valdivia, R. H. cPLA(2) regulates the expression of type I interferons and intracellular immunity to chlamydia trachomatis. J. Biol. Chem. 285, 21625-21635 (2010
52. Gaur, P., Munjal, A. & Lal, S. K. Influenza virus and cell signaling pathways. Med. Sci. Monit. 17, 148-154 (2011
53. Sithisarn, P., Michaelis, M., Schubert-Zsilavecz, M. & Cinatl, J. Differential antiviral and anti-inflammatory mechanisms of the flavonoids biochanin A and baicalein in H5N1 influenza A virus-infected cells. Antiviral Res. 97, 41-48 (2013
54. Lee, S. M. Y, et al. Systems-level comparison of host-responses elicited by avian H5N1 and seasonal H1N1 Influenza viruses in primary human macrophages. PloS One 4, e.0008072 (2009
55. Hui, K. P. Y, et al. H5N1 influenza virus-induced mediators upregulate RIG-I in uninfected cells by paracrine effects contributing to amplified cytokine cascades. J. Infect. Dis. 204, 1866-1878 (2011
56. Nikolova, M. & Asenov, A. Surface flavonoid aglycones in newly studied plant species. Nat. Prod. Res. 20, 103-106 (2006
57. Havsteen, B. H. The biochemistry and medical significance of the flavonoids. Pharmacol. Ther. 96, 67-202 (2002
58. Albers, R, et al. Markers to measure immunomodulation in human nutrition intervention studies. Brit. J. Nutr. 94, 452-481 (2005
59. Fulop, T, et al. Dysregulation of T-cell function in the elderly-scientific basis and clinical implications. Drugs Aging 22, 589-603 (2005
60. Reed, L. I. & Muench, H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-497 (1938